RxDoctor Payments Data

Anil Sharma, MD

Interventional Pain Management · Shrewsbury, NJNPI 1730137878

Payments from drug & device makers

$1,492in general payments, 2019–2025

Across 31 payments — averaging $48.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$312
  • AbbVie$225
  • SPR Therapeutics, Inc$189
  • Intercept Pharmaceuticals, Inc.$129
  • BD$121
  • Medtronic$120
  • plus $396 from 7 others

What the payments were for

  • Food & beverage$1,267100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional pain management providers in New Jerseyto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$382,379
Medicare patients
340
Services billed
15,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl27$14,475
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen149$4,189
Tramadol Hcl ErTramadol Hcl34$3,611
NucyntaTapentadol Hcl11$3,519
Fentanyl26$3,083
Buprenorphine13$2,526
Gabapentin234$2,090
Pregabalin22$1,355
Morphine Sulfate ErMorphine Sulfate54$1,068
Morphine Sulfate63$1,021
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen99$948
Oxycodone Hcl44$571
Duloxetine Hcl25$493
Tizanidine Hcl43$400
Tramadol Hcl105$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta$46$3,51911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional pain management providers in New Jerseyon file to place this against a meaningful peer group, so we don't.

Other interventional pain management in Shrewsbury

Where these figures come from

Is this you, or does something look wrong? →